<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-10T20:43:40Z</responseDate>
  <request identifier="oai:figshare.com:article/34047421" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34047421</identifier>
        <datestamp>2026-10-01T17:23:25Z</datestamp>
        <setSpec>category_7</setSpec>
        <setSpec>category_8</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_39</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_811</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>category_134</setSpec>
        <setSpec>category_135</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Individual neutralising antibody profiles for three example participants across the study period.&lt;/p&gt;</dc:title>
          <dc:creator>Mhairi J. McCormack (25157587)</dc:creator>
          <dc:creator>Louis Banda (5632649)</dc:creator>
          <dc:creator>Stephen Kasenda (6844046)</dc:creator>
          <dc:creator>Ellen C. Hughes (25157590)</dc:creator>
          <dc:creator>Amelia Crampin (272631)</dc:creator>
          <dc:creator>Abena S. Amoah (8605329)</dc:creator>
          <dc:creator>Jonathan M. Read (9159869)</dc:creator>
          <dc:creator>Antonia Ho (10214054)</dc:creator>
          <dc:creator>Brian J. Willett (11450469)</dc:creator>
          <dc:creator>James A. Hay (6066002)</dc:creator>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Microbiology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Ecology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Mathematical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>Virology</dc:subject>
          <dc:subject>Computational  Biology</dc:subject>
          <dc:subject>level bayesian model</dc:subject>
          <dc:subject>boosting following reinfection</dc:subject>
          <dc:subject>april 2022 ).</dc:subject>
          <dc:subject>acute boost remaining</dc:subject>
          <dc:subject>accurate epidemiological inference</dc:subject>
          <dc:subject>403 &amp;# 8211</dc:subject>
          <dc:subject>027 &amp;# 8211</dc:subject>
          <dc:subject>rapid waning underscores</dc:subject>
          <dc:subject>679 neutralising antibody</dc:subject>
          <dc:subject>reconstruct infection histories</dc:subject>
          <dc:subject>quantify antibody kinetics</dc:subject>
          <dc:subject>limited routine surveillance</dc:subject>
          <dc:subject>particularly among adults</dc:subject>
          <dc:subject>malawi &lt;/ p</dc:subject>
          <dc:subject>infection histories</dc:subject>
          <dc:subject>routine surveillance</dc:subject>
          <dc:subject>antibody waning</dc:subject>
          <dc:subject>antibody kinetics</dc:subject>
          <dc:subject>uninfected participants</dc:subject>
          <dc:subject>understanding transmission</dc:subject>
          <dc:subject>traditional seroconversion</dc:subject>
          <dc:subject>three months</dc:subject>
          <dc:subject>sustained protection</dc:subject>
          <dc:subject>serological measurements</dc:subject>
          <dc:subject>saharan africa</dc:subject>
          <dc:subject>responses varied</dc:subject>
          <dc:subject>regional differences</dc:subject>
          <dc:subject>reactivity suggests</dc:subject>
          <dc:subject>prior variants</dc:subject>
          <dc:subject>one year</dc:subject>
          <dc:subject>measured using</dc:subject>
          <dc:subject>individuals clustering</dc:subject>
          <dc:subject>improved understanding</dc:subject>
          <dc:subject>high responders</dc:subject>
          <dc:subject>finding populations</dc:subject>
          <dc:subject>declined rapidly</dc:subject>
          <dc:subject>complicating interpretation</dc:subject>
          <dc:subject>based thresholds</dc:subject>
          <dc:subject>ancestral b</dc:subject>
          <dc:subject>analysed 15</dc:subject>
          <dc:subject>675 unvaccinated</dc:subject>
          <dc:subject>41 vs</dc:subject>
          <dc:description>&lt;p&gt;Antibody titres against each of the SARS-CoV-2 variants were measured using an HIV(SARS-CoV-2) pseudotyped virus neutralisation assay and transformed using log&lt;sub&gt;3&lt;/sub&gt;(titre/50) to match the dilution range.&lt;/p&gt; &lt;p&gt;(SVG)&lt;/p&gt;</dc:description>
          <dc:date>2026-10-01T17:23:08Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pgph.0007133.s012</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Individual_neutralising_antibody_profiles_for_three_example_participants_across_the_study_period_p_/34047421</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
